- ROUNDTABLE: Pharmacy’s future in sync with technology
- EXPERT BLOG: Provider status for pharmacists — one way or another
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- Study from NCPA sheds new light on med synchronization programs
- NCPA: Community pharmacy has historically helped patients as they transition to new health plans
DUBLIN — A federal court in New Jersey has blocked an attempt by Mylan to market a generic version of a drug made by Warner Chilcott.
Warner Chilcott announced Thursday that the U.S. District Court for the District of New Jersey granted its motion for a preliminary injunction against Mylan to prevent it from launching a generic version of the antibiotic Doryx (doxycycline) in the 150-mg strength until the court makes a decision relating to a patent covering the drug, which Warner Chilcott and Mayne Pharmaceuticals allege Mylan to have infringed.
According to IMS Health, Doryx in the 150-mg strength represents more than 95% of Warner Chilcott's entire Doryx franchise based on total prescriptions.